Arbutus Biopharma Corporation - Product Pipeline Review - 2016

Published: Jun, 2016 | Pages: 49 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Arbutus Biopharma Corporation - Product Pipeline Review - 2016

Summary

Global Markets Direct's, 'Arbutus Biopharma Corporation - Product Pipeline Review - 2016', provides an overview of the Arbutus Biopharma Corporation's pharmaceutical research and development focus. 

The report provides comprehensive information on the therapeutics under development by Arbutus Biopharma Corporation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Arbutus Biopharma Corporation
- The report provides overview of Arbutus Biopharma Corporation including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report assesses Arbutus Biopharma Corporation's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report features Arbutus Biopharma Corporation's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons To Buy

- Evaluate Arbutus Biopharma Corporation's strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Arbutus Biopharma Corporation
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Arbutus Biopharma Corporation's pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Arbutus Biopharma Corporation Snapshot 6
Arbutus Biopharma Corporation Overview 6
Key Information 6
Key Facts 6
Arbutus Biopharma Corporation - Research and Development Overview 7
Key Therapeutic Areas 7
Arbutus Biopharma Corporation - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Partnered Products 11
Partnered Products/Combination Treatment Modalities 12
Pipeline Products - Out-Licensed Products 13
Out-Licensed Products/Combination Treatment Modalities 14
Arbutus Biopharma Corporation - Pipeline Products Glance 15
Arbutus Biopharma Corporation - Clinical Stage Pipeline Products 15
Phase II Products/Combination Treatment Modalities 15
Arbutus Biopharma Corporation - Early Stage Pipeline Products 16
Preclinical Products/Combination Treatment Modalities 16
Discovery Products/Combination Treatment Modalities 17
Arbutus Biopharma Corporation - Drug Profiles 18
ARB-1467 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
AB-423 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
ARB-1740 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
ARB-199 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
ARB-596 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
CCC-0346 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
CCC-0975 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
CYT-003QbG10 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Small Molecules to Inhibit HBsAg for Hepatitis B 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
DVR-23 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Small Molecules for Hepatitis B Infection 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Small Molecules to Agonize Sting Receptor for Hepatitis B 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Small Molecules to Inhibit Ribonuclease H for Hepatitis B 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Arbutus Biopharma Corporation - Pipeline Analysis 35
Arbutus Biopharma Corporation - Pipeline Products by Target 35
Arbutus Biopharma Corporation - Pipeline Products by Route of Administration 36
Arbutus Biopharma Corporation - Pipeline Products by Molecule Type 37
Arbutus Biopharma Corporation - Pipeline Products by Mechanism of Action 38
Arbutus Biopharma Corporation - Recent Pipeline Updates 39
Arbutus Biopharma Corporation - Dormant Projects 44
Arbutus Biopharma Corporation - Discontinued Pipeline Products 45
Discontinued Pipeline Product Profiles 45
INX-3280 45
NVP-018 45
RNAi Oligonucleotide to Inhibit CSN5 for Hepatocellular Carcinoma 45
RNAi Oligonucleotide to Inhibit WEE1 for Hepatocellular Carcinoma 45
Small Molecules for Dengue 46
TKM-100802 46
TKM-130803 46
TKM-ALDH2 46
TKM-GSD 46
TKM-HTG 46
TKM-Marburg 46
TKM-PLK1 46
TKMApoC-3 46
Arbutus Biopharma Corporation - Locations And Subsidiaries 47
Head Office 47
Other Locations & Subsidiaries 47
Appendix 48
Methodology 48
Coverage 48
Secondary Research 48
Primary Research 48
Expert Panel Validation 48
Contact Us 48
Disclaimer 49

List of Tables

Arbutus Biopharma Corporation, Key Information 6
Arbutus Biopharma Corporation, Key Facts 6
Arbutus Biopharma Corporation - Pipeline by Indication, 2016 8
Arbutus Biopharma Corporation - Pipeline by Stage of Development, 2016 9
Arbutus Biopharma Corporation - Monotherapy Products in Pipeline, 2016 10
Arbutus Biopharma Corporation - Partnered Products in Pipeline, 2016 11
Arbutus Biopharma Corporation - Partnered Products/ Combination Treatment Modalities, 2016 12
Arbutus Biopharma Corporation - Out-Licensed Products in Pipeline, 2016 13
Arbutus Biopharma Corporation - Out-Licensed Products/ Combination Treatment Modalities, 2016 14
Arbutus Biopharma Corporation - Phase II, 2016 15
Arbutus Biopharma Corporation - Preclinical, 2016 16
Arbutus Biopharma Corporation - Discovery, 2016 17
Arbutus Biopharma Corporation - Pipeline by Target, 2016 35
Arbutus Biopharma Corporation - Pipeline by Route of Administration, 2016 36
Arbutus Biopharma Corporation - Pipeline by Molecule Type, 2016 37
Arbutus Biopharma Corporation - Pipeline Products by Mechanism of Action, 2016 38
Arbutus Biopharma Corporation - Recent Pipeline Updates, 2016 39
Arbutus Biopharma Corporation - Dormant Developmental Projects,2016 44
Arbutus Biopharma Corporation - Discontinued Pipeline Products, 2016 45
Arbutus Biopharma Corporation, Subsidiaries 47